@article{Hidman_Larsson_Thulin_Karlsson_2023, title={Increased plasma endostatin and GDF15 in indolent non-Hodgkin lymphoma}, volume={128}, url={https://ujms.net/index.php/ujms/article/view/9392}, DOI={10.48101/ujms.v128.9392}, abstractNote={<p><strong>Background</strong>: Increased microvascular density correlates with more advanced disease and unfavorable overall survival in non-Hodgkin lymphoma (NHL), suggesting that angiogenesis is important for disease progression. However, studies of anti-angiogenic agents in NHL patients, have generally not shown favorable outcomes. The aim of this study was to investigate whether plasma levels of a subset of angiogenesis-associated proteins are increased in indolent B-cell derived NHL (B-NHL) and to investigate whether the levels differ between patients with asymptomatic versus symptomatic disease.</p> <p><strong>Methods</strong>: Plasma levels of growth differentiation factor 15 (GDF15), endostatin, matrix metalloproteinase 9 (MMP9), neutrophil gelatinase-associated lipocalin (NGAL), long pentraxin 3 (PTX3), and galectin 3 (GAL-3) were measured by ELISA in 35 patients with symptomatic indolent B-NHL, 41 patients with asymptomatic disease, and 62 healthy controls. Bootstrap t-tests were used to assess the relative differences in biomarker levels between groups. Group differences were visualized using a principal component plot.</p> <p><strong>Results</strong>: Mean plasma endostatin and GDF15 levels were significantly higher in symptomatic and asymptomatic lymphoma patients than in controls. Symptomatic patients had higher mean MMP9 and NGAL than controls.</p> <p><strong>Conclusions</strong>: The finding of increased plasma endostatin and GDF15 in patients with asymptomatic indolent B-NHL suggests that increased angiogenic activity is an early event in indolent B-NHL disease progression.</p&gt;}, number={1}, journal={Upsala Journal of Medical Sciences}, author={Hidman Josefin and Larsson Anders and Thulin Måns and Karlsson Torbjörn}, year={2023}, month={May} }